High dose esomeprazole as an anti-inflammatory agent in sepsis: Protocol for a randomized controlled trial
Authors:
Open Access
- 23 August 2023
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 133, 107319
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute
This publication has 35 references indexed in Scilit:
- Use of Proton Pump Inhibitors for the Provision of Stress Ulcer Prophylaxis: Clinical and Economic ConsequencesPharmacoEconomics, 2013
- Blinding in pharmacological trials: the devil is in the detailsArchives of Disease in Childhood, 2013
- Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleedingAdvances in Therapy, 2010
- The Safety of Drugs Used in Acid-related Disorders and Functional Gastrointestinal DisordersGastroenterology Clinics of North America, 2010
- pH‐dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidityInternational Journal of Cancer, 2010
- Metabolic acidosis in patients with severe sepsis and septic shock: A longitudinal quantitative studyCritical Care Medicine, 2009
- Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer BleedingAnnals of Internal Medicine, 2009
- Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic reviewCritical Care, 2008
- Pattern of Proton Pump Inhibitor Calls to Texas Poison Centers, 1998–2004Journal of Toxicology and Environmental Health, Part A, 2007
- Effect of the H, K–ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in miceThe Journal of Nutritional Biochemistry, 2004